Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted by Law360, in “Theranos Scrutiny Shows FDA’s Murky Oversight of Lab Tests.” (Read the full version – subscription required.)
Following is an excerpt:
"The FDA has cleared one test [by Theranos], but the step in front of them on the Nanotainers is still a big step," Bradley Thompson of Epstein Becker Green said. "And that's not a trivial thing because folks have known for decades that people prefer a small amount of blood drawn, but there are really significant scientific obstacles to getting an accurate test that way."